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C022 is• gtne that codes for ,1 pn:,tt1n by tht s.1me ~me This protem 1s 
no~lly oprnsed on tl\t ~ of k~ll. whert 1t p.irtlopiltH in the 
ctlrs ~ In ~ttd studif!s. CD22 ~ bttn shown to •PPHr on 
cancerous lung ceGs.. It a ~ that ttus rS also true for can"rous 
anNn and pmcrHbC ~ d'-" to a~ ;1bnormi1lity common to 
•II of tht1.e anctn. 
The pntNry hypothests a that iNppropNte KtMtlOn of the (022 aene 
ar,es ,1 tumor cd Ml ~tart to ffif!OSU:S&S to tymph nodes ,1nd bone. 
This resHrth tl5S thts hypothts,i:s by comp,ilnng the e.xp~n of CD22 
Up"'5,,S,10n on B-aO WW1 'NM ~r.il owmn cancer ctll Ii~ to detenmne 
o:~ Pil~ Ind by CNIXttnZJtlOf'I of nonNI and •bernnt CD22 
recfPU)( substnte W'ltff'ietlcns on bone rNITOW strorNI cells. 
This reseMCh MS Vf'.ll scn,fiata. It WIii pnMde valuable inform,1tion 
on the exprt'SSion of CD22 on tumors. wh,ch an m tum be used ,1s a~ 
t'if1'l for ,nt.body darmed ~PY Anbbody thMapy for this protein ;also 
~s IT"•t poW'lbll \ti ~ V1d pil~•tJC anctn. as it ,s t-a11ortd with 
lffilN" ~oty tNn rn.,y a...fflT. QrUf trHU'Mnts 
~ 
What r1 CD2l? 
(022 ii• cene tNt c:ode for ,1 Qrbohydrite bmd1ng lectin protein wh1th 
11 ilso ailed Bl,<AM ~r.c KJd bl:nd<"11&-H:e lKtlll 2. This protein tS 
normally__....., on !he OUltf nwml><>ne suma of 8-lymphocytos, 
WMrt 1t pal'tlOpat.ts tn 8-all $,W'Vl'V3J. In r, i.te-d stud.es, C022 illS bttn 
shown to Jppur on Qf'IUfOUS lune crlls Thrs study IS performe-d under the 
hypothHas tNt thrs rs i:l,0 true for a~ ~ Nn ind pancrutlC cells 
t>K.iuse of ill chromosome 11:JinonNhty common in ill of the 
Jfortmenboned ancm C022 may mo part1CJp.iite 1n boM meustaSts 
through CD22 hom1nc rfU'Pt(W KtMty prcMchnc a mtta:statx: iCMnug, to 
the " II, wh1Ch rl a part of whit this research Sttks to determine. 
Hypothesb 
The centnil hypothnn rs tNt tUfflOf c.efts w,th a rearrangement 1n the 
re1k>n of chromosome 19qU ~ in Jdvin~e to meu staSJs to lymph 
nodH ind bone This rnHrch tf'StS tM hypothn,s by compannc the 
e11preu10n of CD22 oprHSK>t'I on a-aa lanes w th stYtnil ownan anur 
cell Imes to determine expression patttrns ind by charactet1zat1on of 
normal ind abtrnnt CD22 ff<tl)tof" substrate 1nterxt10ns on bent marrow 
strOf'Nlctlls 
Reb1ted Rese.uch 
Vinous stud,es provide evtdence for C022 bt1l"'i ill potent.al muttr '::i· 
potent111 an11body treatment for lune c,nct>r (Tl.llC.I f'l ii 2012 
rt~1rch Is controversial, though, u one study (Poi et at 20141 p 
uNble to tirget CD22 w,th their ~lf't'.ed i1nt bodi 
Alm of this resurth 
This resurch sttks to provldt 1ns1ght 1n10 thl" i1be 
C022 on tumors Th11 inform.t.,on an be 
prott1n to Jt\O i11C1 ~\ a t 
c.incrr1 
Emily M.R. Marshall and David Pearson, Ph.D. 
The University or Texas At Tyler, Tyler, TX 
ITm!fflffl 
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Tissue Culture 
~ ' I 
fit!n l.t (tool ~ ~~ono, 
lo l",tA. 
~)blbonom.lck,-cU •1t'ltN1,,..11 
t\11'1 loloww\e •mpliflullOII c,I llw ([)HA A 
"°"'1'1'l'l""-l-'11tP',..l«1111l 
control-• ihoN"' •~ thtcOfr,IA 
A mammalian cell tissue culture was performed on two cancerous ovarian cell lints (PA· l). These cell lines were 1rown and 
maintained under st!rilt conditk>ns in an environmentilty controlled chaimber with a S" carbon dk>xide atmcnphere at 
3TC. These cells were grown using DMEM medium, fetal bovine serum (f6S), and antib.Otic.s. 
Primer Desicn 
Primers for this procedure were designed by util1zin1 NC Bi's Primer-BLAST function; pnmers anew tarceting of the desirtd 
gene prodlJCt. In this case, that gtne is C022. The introns for this gene were mapped to determine the coding re1ions of 
(022. (Figure 1). 
Reverse Transaiptase Potymense Chain Ruction (RT PCR) 
A sample of the PA-1 cell line was harvested for RNA, which was punfied, quantrtated using a nanodrop, and assessed for 
quality via gel electrophorHIS (Figure 2a) All of the samplfi in this experiment were stained UJJnl GelRed A ladder was run 
in each gtl as a method of mtasunng the lengths of tht samples. The RNA was then rf'Vtrse trans.c:nbed to cDNA thtn the 
sptcific CD22 sequence was amphf1ed by us1ng an upstream and a downstream primer des1gntd for (022, whlCh span an 
intton. Anothtr gel was run on the cDNA prodlKt (Figure 2b). 
Flow Cytometry 
Flow cytomttry 1nvotves a laser-based technology :r, <e!J co~--.:.ng. sorting. and b,omarker detection analysis. The flow 
i1natys1s 1s being ~rformed on a ll«iUTia"I Cou:ter C~'tCf!~, .\:.a",;:s ,s performed by suspending cells in isotonk solution, 
a1mng with nuorescentty labeled ant;boc an:; 1~en ~na:,.-u,g 1ne cp!ls on th!! mm ument. The cell lines are anJtyzed 
<1 the ~mt detector settin&s In this study, no,... C)!~ -r,t•r1 s bt ~g used to assess the frequency of C022 sur1Ke 
'"' anc.rrous ovarian eel ' •nt1 (Figurr 31 ~r-".,.) tf:b ,1re- used as ,1 positive control for C022 surface expresSJon, 
c·1ntrol for nonsi,tcific b,nding by u·.e tr: ::::vd1 
Northtrn and \'/es-tern Bloninz 
Nonhtrn blctt.n;,.,, t, u1 , : 
anafys,s 1s unablt to anJtvze this, .,..r .. • 
the mRNA of the S-cell (Ramos), this rr. ,, 
the length of C022 on the surface of tl'\e o,· 
t~~-· ~,s .,..ould te:1 us if rt 1s the appropnate sued ~nscript PCR 
• citrlorrr.mg a Northern blot. If the mRNA 1s a different size than 
c.f rve-st1gat10n. Western blorung will be used to determine 
Wh.1t Has Been Obserwd So Far 
In qualrtative anatys1s of the total RNA prior to pef"fOl'mlnc rwerw 
t~nscription (Figure 2a), thue .1re two ~ nch Jnd tvldtnce ot rlbo1omaJ 
RNA at Vilt"yine lengths, 1ndatm1 the RNA rs ,nuct it this met Ficure lb 
depicts a gtl th.1t wu run f0Uowln1 rtwrse tr.1nscrlpt1on and PCR 
amphfkation. While fainter compared to the ~mos lkell) band. I definite 
b.1nd Is pre-sent for the PA· l cONA. This U5'ef'U th.at C022 Is v:prnsed 
fnappropnatety In cancerous PA· l ovarian ctlls. howeYer, 1111 not exprniec, 
at the levels seen In tht Ramos ctlls 
PA· l ovarian cells are the onty cells that haw been an,lyted thus f.1r V\a 
flow cytometrv. The d1Hertnc.t ,n muns be1wttn the lc(j PA-1 controA Jnd 
the PA· 1 C022 population ~nds conf.cSence to C022 surface uprtssk>n In 
this cell line. Flow cytometry hills yet to bit oot1m1zed for 1h11 experlrMnt, and 
more cell lines and neptive controls will bf analyud U\lnl now cvtom«try 
Hela, the ne1at1ve control used. pr~ to be a poor control upon Row 
cytomet,v. 
Where This Study Will Go In the Fvturt 
This preliminary study has a lot of sp,ac.e to continue New cells !Inti and 
controls will bt explored, and PCR will be performed on thne, one such cell 
line being CaOVl. Tht PCR proc:IUCU wlll be wqutnctd to confirm the rtSUIU 
In ordtr to proceed i nd conskSer the PCR sucuuful. the SfqutnU mutt 
mi1tch that of CD22. Northern ind wenem blottlrc rT\<1'f bt ~med ,n the 
near future. To fully addren the primi11ry ~ s,\ of th1.s rtSe.ardl, the 
functionality of C022 on thHe cells will al:so nttd to bt aplortd. Fvwre 
e•perimenu would test the adhes,on of C022 expr~.sinc cen.s to bone 
marrow stromal cells. Should this research come to the condus,on that the 
hypothesis was accur1te, animal tntlnc and d1nial tNk would be amonc 
the final assessments of CD22 as a viah'e tarpt fOI' arruboay thtrapy 
~ 
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